Although anti-CD137 mAb has not been effective as a monotherapy in HNSCC models, it has been shown to synergize with chemoradiation in a model of HPV+ HNSCC to inhibit tumor growth [20, 21]. This evidence concerns the gene TNFRSF9 and head and neck squamous cell carcinoma.